NCT06525246 - Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Stage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CancerEGFR Mutation-Related Tumors

Interventions

DRUG

ONO-7475

Specified dose, once daily

DRUG

Osimertinib Mesylate

Specified dose, once daily

Trial Locations (13)

Unknown

National Hospital Organization Shikoku Cancer Center, Matsuyama

Kobe City Medical Center General Hospital, Kobe

Hyogo College Of Medicine College Hospital, Nishinomiya

Kitasato University Hospital, Sagamihara-shi

Kanagawa Cancer Center, Yokohama

Saitama Cancer Center, Ina

University Hospital Kyoto Prefectural University of Medicine, Kyoto

Osaka International Cancer Institute, Osaka

Osaka Medical and Pharmaceutical University Hospital, Takatsuki

Shizuoka Cancer Center, Nagaizumi-chō

The Cancer Institute Hospital Of JFCR, Koto-Ku

Tokyo Medical University Hospital, Shinjuku-Ku

Nigata Cancer Center Hospital, Niigata